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Allergic asthma is characterized by chronic airway inflammation and hyperreactivity
and is thought to be mediated by an adaptive T helper-2 (Th2) cell-type immune resp-
onse. Here, we demonstrate that type 2 pulmonary innate lymphoid cells (ILC2s) sig-
nificantly contribute to production of the key cytokines IL-5 and IL-13 in experimental
asthma. In naive mice, lineage-marker negative ILC2s expressing IL-7Rα, CD25, Sca-1,
and T1/ST2(IL-33R) were present in lungs and mediastinal lymph nodes (MedLNs), but
not in broncho-alveolar lavage (BAL) fluid. Upon intranasal administration of IL-25 or
IL-33, an asthma phenotype was induced, whereby ILC2s accumulated in lungs, MedLNs,
and BAL fluid. After IL-25 and IL-33 administration, ILC2s constituted ∼50 and ∼80% of
IL-5+/IL-13+ cells in lung and BAL, respectively. Also in house dust mite-induced or
ovalbumin-induced allergic asthma, the ILC2 population in lung and BAL fluid increased
significantly in size and ILC2s were a major source of IL-5 or IL-13. Particularly in OVA-
induced asthma, the contribution of ILC2s to the total population of intracellular IL-5+
and IL-13+ cells in the lung was in the same range as found for Th2 cells. We conclude
that both ILC2s and Th2 cells produce large amounts of IL-5 and IL-13 that contribute to
allergic airway inflammation.
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Introduction
Allergic asthma is characterized by a predominant eosinophilic
airway inflammation, airway hyperreactivity, and a chronic T
helper-2 (Th2) cell-type of immune response to various allergens,
such as house dust mites (HDMs), molds, or animal dander [1,2].
Available experimental models for asthma indicate that allergen-
specific Th2 cells are key players in induction and maintenance of
allergic asthma [3]. These cells produce vast amounts of cytokines
Correspondence: Dr. Rudi W. Hendriks
e-mail: r.hendriks@erasmusmc.nl
that induce IgE synthesis (IL-4), recruit eosinophils and mast cells
(via IL-5 and IL-9, respectively), and cause smooth muscle hyper-
reactivity via IL-13 (reviewed in [4]).
Although adaptive Th2 cells have been identified as important
sources of IL-4, IL-5, and IL-13 [5], many recent studies emphasize
the importance of innate cells in cytokine production, including
but not limited to mast cells, eosinophils, and basophils. Next to
the canonical NK and lymphoid-tissue inducer (LTi) cells, a grow-
ing family of cytokine-producing “helper” innate lymphoid cells
(ILCs) has been identified [6]. Interestingly, a lineage-negative
ILC population that produces high amounts of IL-5 and IL-13
was identified in fat-associated lymphoid clusters (FALCs) and
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mesenteric lymph nodes [7–9]. These cells were named natural
helper cells, nuocytes, or multipotent progenitors and, because of
their Th2 cytokine production, they have been dubbed type 2 ILCs
[6]. ILC2s play a role in defense mechanisms and (re)shaping im-
mune and nonimmune tissues and can be stimulated with IL-25
and IL-33. In a Nocardia brasiliensis infection model, ILC2s were
essential and sufficient for clearance of this helminth from the mu-
cosa, even in the absence of the adaptive immune system [7,9].
Recently, various groups demonstrated the presence of ILC2s
in the respiratory system of mice and humans [10–12]. ILC2 were
shown to accumulate in the lungs of mice after infection with
influenza virus, via an IL-33 dependent mechanism. These ILC2
induced airway hyperreactivity through IL-13 secretion [10] and
also restored airway epithelial integrity and lung function and con-
tributed to airway remodeling by the production of amphiregulin
[12]. In addition, ILC2s were found in nasal polyps of patients
with chronic rhinitis, a classical Th2 disease [11].
IL-25 is a member of the IL-17 cytokine family that is expressed
in human and mouse in response to allergens, particles, and
helminth infection [13–15]. Administration of IL-25 was shown
to induce IL-4, IL-5, and IL-13 production, even in the absence
of B and T lymphocytes in recombination activating gene (Rag)-
deficient mice [15]. The main sources of IL-25 in asthma are
the lung epithelium, eosinophils, mast cells, and basophils [16].
Moreover, IL-25 amplifies Th2 responses and causes increased
eosinophilic infiltration in mice [17]. IL-33 belongs to the IL-1
family and binds a receptor complex consisting of the IL-1R acces-
sory protein and ST2 [18]. The membrane-bound form of ST2 is
highly expressed on mast cells and Th2 cells [19,20], associat-
ing the IL-33 pathway with Th2 conditions. IL-33 is produced by
epithelial cells in the lung [18] and epithelial expression of IL-33
increases in asthmatics [21]. The importance of IL-25 and IL-33 for
asthma is underlined by the finding that disruption of the IL-25 or
IL-33 pathway prevents induction of allergic airway inflammation
in mice [22,23]. Several studies have identified lineage-negative
cells in the lung that manifest IL-5 and IL-13 production in resp-
onse to IL-25 [14,24] or IL-33 [25,26] administration in mice.
In this report, we investigated the presence of ILC2s in the res-
piratory tract and hypothesized that pulmonary ILC2s are involved
in allergic asthma by production of Th2 cytokines. We found that
ILC2s produced substantial amounts of IL-5 and IL-13 in various
murinemodels of allergic lung inflammation, both upon intranasal
administration of IL-25 or IL-33 and in house dustmite (HDM) or
ovalbumin (OVA)-induced asthma. We conclude that both ILC2s
and Th2 cells produce large amounts of IL-5 and IL-13 that con-
tribute to allergic inflammation in asthma.
Results
Identification and characterization of pulmonary
ILC2s
To explore the presence of ILC2s in the respiratory tract, we
used flow cytometry and analyzed lung, mediastinal lymph node
(MedLN), broncho-alveolar lavage (BAL), and thoracic fat of
naive wild-type mice. We identified a lineage-negative, low side
scatter population expressing IL-7Rα (CD127), T1/ST2 (IL-1RL1,
a subunit of IL-33R), partially positive for c-Kit (CD117), stem
cell antigen Sca-1 (Ly6A/E), and IL-2Rα (CD25) in the lung (Fig.
1A). This population resembled the recently identified popu-
lation of ILC2s in gut-associated tissue and influenza infected
lungs [6,7,9,10,12]. Sca-1 expression levels were higher in B6
mice than in BALB/c mice (data not shown). As ILC2s were
initially found in fat-associated lymphoid tissue, we analyzed
the thoracic fat attached to the thorax wall and around the
aorta, and found varying but steadily limited numbers (<200)
of Lin−T1/ST2+CD127+c-Kit+ cells. These ILC2s were present in
the lung and MedLNs of naive mice, but virtually absent in BAL
(Fig. 1B).
Pulmonary ILC2s depend on common gamma chain
cytokine signals
Pulmonary ILC2s were present in the lungs of C57BL/6 and
BALB/c mice (Supporting Information Fig. 1). Intestinal ILC2s are
found in Rag2−/− mice, but their development or survival depends
on the common gamma (γc) chain, as Rag2/Il2rg double-deficient
mice lack ILC2 [7]. Accordingly, we found pulmonary ILC2s in
comparable numbers in the lungs and MedLNs of Rag1−/− mice,
but not in Rag2/Il2rg double-deficient mice (Supporting Informa-
tion Fig. 1). We noticed that the absence of Myd88, an adapter
molecule that functions downstream of TLRs and IL-33R [27],
had no significant effect on ILC2 numbers in the lung. IL-22 is an
important cytokine in the lung and in the intestine for protection
of epithelial surfaces [28] and is rapidly produced in conjunc-
tion with IL-17 by LTi cells. We detected no significant alterations
in lung ILC2 numbers in Il22−/− mice (Supporting Information
Fig. 1). Closely related ILC populations, including ILC17 [29] and
ILC22 [30–33], depend on the RORγt transcription factor for their
development, while intestinal ILC2s do not express RORγt, but
RORα and RORβ instead [7]. In agreement with this finding, pul-
monary ILC2s were present in mice deficient for the Rorc gene,
encoding RORγt (Supporting Information Fig. 1).
In summary, we found that development of pulmonary ILC2s
requires signaling via a γc-dependent cytokine pathway. Because
of the high levels of IL-7Rα (CD127), it is conceivable that IL-7
signals are important for ILC2 development.
Pulmonary ILC2s produce IL-5 and IL-13 Th2
cytokines
ILC2s produce large amounts of the Th2 cytokines IL-5 and
IL-13 upon phorbol myristate acetate (PMA) and ionomycin stim-
ulation [7,9]. When we stimulated lung cell suspensions with
PMA/ionomycin for 4 h and probed for production of the Th2
cytokines by intracellular flow cytometry, we detected fractions of
ILC2s positive for IL-5 and IL-13, while IFN-γ+ and IL-4+ ILC2s
were hardly detectable (Fig. 1C). Quantitative RT-PCR analysis of
sorted lin−CD127+ T1/ST2+ cells from naive mice stimulated in
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Figure 1. Pulmonary ILC2s are present in the respiratory tract of naive mice. (A) Flow cytometric identification of pulmonary ILC2s is shown.
Single-cell suspensions of collagen-treated lungs, thorax fat, and mesenteric fat of naive BALB/c mice were analyzed by flow cytometry. Cells
negative for lineage markers were analyzed for expression of IL-33R (T1/ST2) and CD127 (IL-7Rα). T1/ST2+IL-7Rα+ cells were gated and analyzed
for c-Kit (CD117), Sca-1, and IL-2Rα (CD25), shown as histograms. Proportions of cells within the gates are given. FSC: Forward Scatter. (B) The
quantification of ILC2s (Lin−CD45+CD127+T1/ST2+CD25+ cells) in the pulmonary tract is shown. MedLN: mediastinal lymph node; BAL: broncho-
alveolar lavage. Data are shown as mean + SEM of n ≥ 2 animals per group and all data are representative of four independent experiments.
(C) Intracellular cytokine content of ILC2s is shown. Lin–CD127+ T1/ST2+ lymphocytes were gated and analyzed for CD45 versus the indicated
cytokines. Results are shown as dot plots. Single-cell suspensions were stimulated with PMA/ionomycin in the presence of monensin for 4 h.
(D) RT-PCR quantification of Il5 expression of the indicated FACS-sorted ILC2 cell suspensions, as well as polarized T-cell cultured under Th0,
Th1, and Th2 conditions is shown. Il5 levels were normalized to Actb levels. Data are shown as mean + SEM of n ≥ 3 samples per group for ILC2
populations and one sample per group for Th populations and data are representative of two independent experiments.
vitro with IL-2, IL-25, and IL-33 showed that lung ILC2 expressed
higher levels of Il5 than BAL ILC2, FALC ILC2, or in vitro cultured
polarized Th2 cells (Fig. 1D).
Pulmonary ILC2s are induced in IL-25- and
IL-33-induced asthma
Although classic animal models of experimental asthma depend
on sensitized Th2 cells, intranasal administration of IL-25 or
IL-33 in mice have also been reported to induce an asthma pheno-
type with airway hyperresponsiveness, eosinophilic inflammation,
mucus hypersecretion, and Th2 cytokine production in the lung
[14,25,34]. Since ILC2s are reported to release cytokines in re-
sponse to IL-25 or IL-33 stimulation [7,9], we hypothesized that
pulmonary ILC2s contribute to airway inflammation in cytokine-
induced asthma. Mice were intranasally treated with five doses
of IL-25 or three doses of IL-33 and analyzed 24 h after the last
instillation (Fig. 2A). While we observed no significant increase
in BAL cellularity in IL-25 treated mice, IL-33 induced a strong
increase in total cellularity, eosinophils, and T cells in BAL fluid
(Fig. 2B), indicating the onset of airway inflammation. Likewise,
lung cellularity also increased upon IL-33 administration (Fig. 2C).
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Figure 2. Administration of IL-25 and IL-33 induces eosinophilic airway inflammation and increases ILC2 numbers. (A) Scheme for IL-25 and
IL-33 treatment of BALB/c mice. Isoflurane-anesthesized animals received 1 μg intranasal administrations of the indicated cytokines (or PBS as a
control) on the days marked with a circle and were analyzed 24 h later. (B) The quantification of indicated cell populations in the BAL fluid after
cytokine treatment is shown. (C) The total number of cells in the lungs of treated animals is shown. (D) Flow cytometric identification of pulmonary
ILC2s (gated) in single-cell suspensions of the lungs of treated mice. Plots show expression of the indicated markers on cells negative for lineage
markers. Numbers indicate the frequency of ILC2s in the total lymphocyte population ± SEM using the gates indicated. (E) Quantification of ILC2s
in different compartments of the pulmonary tract is shown. (B, C, E) Data are shown as mean + SEM of n = 3–4 mice per group and all panels
are representative of two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA analysis followed by Turkey post-tests to
analyze statistical significance between PBS control versus treated animals. ns: not significant.
Administration of IL-25 and IL-33 induced upregulation of T1/ST2
on ILC2s (Fig. 2D). The number of ILC2s strongly increased inmice
treated with IL-33 (Fig. 2E).
Pulmonary ILC2s are the major cytokine producing
lymphocytes in IL-25- and IL-33-induced asthma
Next, we determined the contribution of ILC2s to production of
IL-4, IL-5, and IL-13 in cytokine-induced airway inflammation by
intracellular flow cytometry. We observed that intranasal treat-
ment with PBS alone induced increased production of IL-5 and
IL-13 (Fig. 3A, compared with naive mice, Fig. 1C). Treatment
with IL-25 or IL-33 further increased the fraction of IL-5 and
IL-13+ ILC2s to more than ∼80 and ∼60%, respectively, while
IL-4 production remained low (Fig. 3A). Comparisons with
cytokine content of T1/ST2+ CD4+ T-cell fractions, which are
enriched for Th2 polarized cells [20], and T1/ST2− CD4+ T-cell
fractions, revealed that the ILC2 population comprised most of
the IL-5+ and IL-13+ lymphocytes upon treatment with IL-25 and
IL-33 (up to 3.4 × 106 IL-5+ and 3.1 × 106 IL-13+ cells/lung after
IL-33 treatment, respectively) (Fig. 3B). The contribution of ILC2s
to IL-4 production strongly increased upon IL-33 but not upon
IL-25 administration. Likewise, IL-25 and IL-33 activated IL-5 and
IL-13 production in ILC2s in BAL fluid (Supporting Information
Fig. 2A). After treatment with IL-25 and IL-33, ILC2 became the
most important producers of Th2 cytokines in the BAL (Supporting
Information Fig. 2B).
Taken together, these results show that treatment with IL-25
induced a limited increase in BAL cellularity, whereby pulmonary
ILC2s were potent producers of IL-5 and IL-13. In contrast,
treatment with IL-33 induced a strong increase in total cellularity,
and an increase of the numbers of eosinophils and ILC2s in BAL.
These ILC2 manifested a high cytokine content for IL-5, IL-13,
and to a lesser extent IL-4, all of which contribute to allergic lung
inflammation.
ILC2 population is an important target of IL-25 and
IL-33, independent of the adaptive immune system
Previous studies have shown that IL-25 and IL-33 can induce an
asthma phenotype, even in the absence of B and T lymphocytes
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Figure 3. ILC2s produce important amounts of IL-5 and IL-13 in cytokine-induced airway inflammation. (A) Intracellular cytokine content of
pulmonary Lin−CD25+CD127+T1/ST2+ ILC2s in mice, treated as specified. Plots show forward scatter (FSC) versus the indicated cytokines. Single-
cell suspensions of lungs were stimulated with PMA/ionomycin in the presence of monensin for 4 h. Numbers indicate the proportions of
cytokine-positive ILC2s. (B) Contribution of various cell populations to Th2 cytokine production in the lungs after administration of PBS, IL-25,
or IL-33. Proportions of cytokine expressing cells were determined by flow cytometry (as in panel A) in ILC2, T1/ST2+, and T1/ST2− CD3+CD4+
Th cells. Pie charts and percentages represent the contribution of various populations to the total number of cytokine-producing cells. Data are
representative of two independent experiments with three to four mice per group.
[14,25,34]. Consistent with reported findings [7,8], we found
that ILC2s develop in the absence of Rag1 or Rag2 but are
virtually absent from lungs in mice that lack the γc chain (Sup-
porting Information Fig. 1 and 4A). To investigate whether ILC2s
are activated in the absence of an adaptive immune system, we
employed the cytokine-induced asthma models in Rag2-deficient
(ILC2+) and Rag2/Il2rg double deficient (ILC2−) mice. Admin-
istration of IL-25 and IL-33 resulted in an increase in cellularity
in lung and BAL and eosinophilic inflammation in Rag2-deficient
mice, but not in Rag2/Il2rg double-deficient mice (Fig. 4B). These
findings indicate that a γc chain-dependent population is respon-
sible for inducing airway inflammation upon IL-25/IL-33 adminis-
tration. Administration of IL-33 induced increased ILC2 numbers
in BAL and lung in Rag2-deficient mice, while we observed no
increase in ILC2 numbers in Rag/Il2rg-deficient mice (Fig. 4C).
Treatment of mice with PBS, IL-25, and IL-33 induced production
of IL-5 and IL-13 but not IL-4 in Rag2-deficient lung ILC2 (Sup-
porting Information Fig. 3), demonstrating that ILC2 are activated
in the absence of adaptive immunity.
In summary, we found that airway inflammation induced by
IL-25 and IL-33 is mediated by a Rag2-independent, γc chain-
dependent population. Moreover, a strong increase in the number
of ILC2s, more than ∼80% of which were intracellular IL-5 and
IL-13+, was induced. Therefore, we conclude that ILC2s are
the most important inducers of eosinophilic inflammation upon
intranasal IL-25 or IL-33 administration.
Pulmonary ILC2s are important cytokine producers in
HDM-induced allergic asthma
Next, we induced allergic asthma in mice with HDM to determine
to which extent ILC2s synergize with an adaptive inflammatory
Th2 response in the respiratory tract. Mice were sensitized with
HDM and challenged either once, three, or ten times with HDM
(Fig. 5A). Mice that were sensitized and challenged with PBS
served as controls. As expected, HDM-challenged mice exhibited
airway inflammation marked by increased cellularity, eosinophilia
and T-cell influx, and BAL fluid, when compared with PBS con-
trols (Fig. 5B). HDM-induced asthma was also accompanied by
increased numbers of ILC2s in lung and BAL, but not in MedLNs
(Fig. 5C), indicating that during the Th2 inflammation ILC2s un-
dergo proliferation or are attracted, possibly by cytokines.
As observed in cytokine-induced airway inflammation, in HDM-
induced allergic asthma pulmonary ILC2s did not only increase
in number, but concomitantly also the proportions of cytokine-
containing cells increased. Intracellular flow cytometry demon-
strated that in HDM-induced allergic asthma ILC2s in the lung
produced IL-5, IL-13, and also IL-4 (Fig. 5D). To determine to
what extent pulmonary ILC2s contribute to cytokine production
in relation to conventional Th2 cells and other Th cells, we calcu-
lated absolute numbers of cytokine-expressing cells in lungs and
BAL. The contribution of ILC2s to IL-4 was limited, compared with
T1/ST2+ or T1/ST2− Th cells, and only detectable in the lung,
where up to ∼1400 ILC2 produced IL-4. In the lung up to ∼1900
of total IL-5+ cells were ILC2s, which is substantial, as compared to
values between 2000 and 4500 for T1/ST2+ or between 1500 and
4800 for T1/ST2− CD4+ T-cell fractions (Fig. 5E). Likewise, up to
2800 ILC2s produced IL-13, while 3200–5800 T1/ST2+ Th2 cells
produced IL-13. Despite the modest numbers of ILC2s detected
in BAL fluid, the number of IL-5 and IL-13 producing ILC2 and
T1/ST2+ Th2 cells were comparable. Collectively, these results
illustrate that pulmonary ILC2s comprised a significant propor-
tion of IL-5+ and IL-13+ cells in lung and BAL in HDM-induced
allergic asthma, whereby the contribution of ILC2 cells to the total
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Figure 4. Induction of airway inflammation by IL-25 and IL-33 depends on a γc chain-dependent cell population. (A) Identification of ILC2s in
the lungs of mice of the indicated strains is shown. Plots show expression of CD25 and T1/ST2 by Lin− CD127+ lymphocytes. Values indicate
the percentage of ILC2 of Lin-negative lymphocytes ± SEM. (B) Quantification of indicated cell population in the BAL fluid of the indicated mice
treated with PBS, IL-25, or IL-33 in BAL and lung is shown. (C) Quantification of Lin−CD25+CD127+T1/ST2+ ILC2s in the pulmonary tract of the
indicatedmice after treatment is shown. (B, C) Data are shown asmean + SEM of n= 2–4mice per group and are representative of two independent
experiments. *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA analysis followed by Turkey post-tests to analyze statistical significance between
PBS control versus treated animals. ns: not significant.
population of IL-5+ and IL-13+ cells in the BAL was in the same
range as found for Th2 cells.
ILC2 are major IL-5 and IL-13 producers in
OVA-induced asthma
Finally, we determined the contribution of ILC2 to cytokine pro-
duction in an OVA-induced asthma model. After i.v. injection of
Th2-polarized T cells bearing the DO11.10 OVA-specific T-cell
receptor [35], mice were challenged five times with OVA aerosols
and analyzed 2 days after the last challenge. In this asthma model,
total BAL cellularity increased to 3.0 ± 0.5 × 106 cells and flow
cytometric analysis revealed that 68 ± 2% of BAL cells were
eosinophils (data not shown), confirming induction of eosinophilic
airway inflammation. Flow cytometric analyses of the lungs re-
vealed that ILC2s contained substantial proportions IL-5+ and
IL-13+ cells, while only small proportions of the cells were IL-4+
(Fig. 6A).
When we determined the contribution of ILC2s to Th2 cytokine
production, we noticed that ILC2s were poor producers of IL-4 in
both lung and BAL, but were major producers of IL-5. In the lung
∼21,000 ILC2s produced IL-5 (compared with ∼32,000 T1/ST2+
Th2 cells), while in BAL ILC2 was the main IL-5-producing cell
population: ∼7500 ILC2s, compared with ∼1900 T1/ST2+ Th2
cells (Fig. 6B). In addition, we found ∼12,000 IL-13 producing
ILC2 in the lung, compared to ∼16, 000 IL-13 producing T1/ST2+
Th2 cells. In contrast, the contribution of ILC2s to IL-13 production
in the BAL was limited.
In summary, these results indicate an important role for pul-
monary ILC2s in the production of IL-5 and IL-13 in OVA-induced
asthma. In particular, pulmonary ILC2s are potent producers of
IL-5 and make up the largest IL-5-producing population in the
BAL fluid in OVA-induced asthma.
C© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
1112 Roel G. J. Klein Wolterink et al. Eur. J. Immunol. 2012. 42: 1106–1116
Figure 5. Pulmonary ILC2s are major Th2 cytokine producers in HDM asthma. (A) Asthma protocols showing sensitization (S) and challenges
(C) with house dust mite (HDM) in BALB/c mice, followed by analysis (A). Control mice were treated with PBS instead of HDM. (B) Flow cyto-
metric quantification of the indicated cell populations in the BAL fluid after various HDM-asthma treatments is shown. (C) Quantification of
Lin−CD127+T1/ST2+ ILC2 numbers in lung, BAL, and mediastinal lymph nodes (MedLNs) of HDM- or PBS-treated animals is shown. (D) The
intracellular cytokine content in HDM-challenged mice is shown. Total lung cell suspensions were stimulated with PMA/ionomycin for 4 h.
CD3−CD4−T1ST2+CD127+ cells were gated and analyzed for the indicated cytokines. Values indicate the proportions of cytokine positive cells
± SEM. (E) Cytokine production by lymphocyte populations in lung and BAL fluid is shown. Bars show the absolute numbers of intracellular
cytokine-positive cells within the indicated lymphocyte populations. (B, C, E) Data are shown as mean + SEM of n > 4 mice per group and are
representative of three experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, unpaired t-test. ns: not significant.
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Figure 6. Pulmonary ILC2s are major Th2 cytokine producers in OVA-induced asthma. (A) Flow-cytometric analysis of intracellular cytokine
content in OVA-challenged mice is shown. Total lung cell suspensions were stimulated with PMA/ionomycin for 4 h. ILC2s were gated as
Lin−CD25+CD127+T1/ST2+. Th cells were gated as T1/ST2+ or T1/ST2− CD3+CD4+ lymphocytes. Values indicate the proportions cells ± SEM
positive for the indicated cytokines. Plots are from representative samples of seven animals per group. (B) Contribution of lymphocyte populations
indicated in panel A to production of IL-4 and IL-5, IL-13 in lungs, and BAL fluid, upon OVA treatment in vivo. Data are shown as mean + SEM of
n = 7 animals. Experiment was performed once.
Discussion
ILC2 were shown to mediate airway hyperreactivity, independent
of the adaptive immune system, in a nonallergic form of asthma
induced by influenza virus infection. However, whether ILC2 have
the capacity to synergize with allergen-specific Th2 cells in allergic
asthma remained unexplored. Our studies in naive mice as well
as in cytokine-, HDM-, and OVA-induced asthma demonstrate the
presence of ILC2s in the pulmonary tract and their substantial con-
tribution to allergic inflammation.We conclude that ILC2s, defined
as non-B/non-T lymphocytes expressing IL-7Rα, CD25, Sca-1,
c-Kit, and T1/ST2/IL-33R are major producers of IL-5 and IL-13,
even in allergen-induced asthma, where Th2 cells are thought to
be the most important sources of IL-5 and IL-13.
It was previously reported that the lineage-negative cells that
produce IL-5 and IL-13 in response to intranasal administration of
IL-25 were T-cell independent, because they were also detected
in Rag2−/− mice [14]. We have now shown that these cells are
ILC2s and we additionally found that they were efficiently in-
duced upon IL-25 or IL-33 administration in Rag2−/− mice, but
not in Rag2/Il2gc double-deficient mice. While our studies were
in progress, two other studies have demonstrated the activation
of ILC2s in response to IL-25 and IL-33 administration [36] or
in response to glycolipid antigens, which activate NKT cells and
thereby induce IL-33 production by alveolar macrophages [37],
although these papers focus on the production of IL-13 by ILC2s.
From our findings, we can conclude that ILC2s are an impor-
tant source of both IL-5 and IL-13, not only in IL-25- or IL-33-
induced allergic lung inflammation, but also in models of al-
lergic asthma based on OVA and HDM allergens. In addition,
we noticed that upon IL-33 stimulation in vivo (Fig. 3A) or in
OVA- or HDM-induced airway inflammation (Fig 5D and 6A) low
but detectable proportions of ILC2 had the capacity to produce
IL-4. We have compared the expression levels of CD127/IL-7Rα,
IL-2Rα, T1/ST2, and Sca-1 by flow cytometry in IL-4, IL-5, and
IL-13 expressing ILC2, but did not detect significant differences.
ILC2s express c-Kit, IL-2Rα, and IL-7Rα, suggesting a lymphoid
origin. Although the exact nature of ILC2 precursors remains un-
known, recent data confirm that bone marrow lymphoid-primed
multipotent progenitors and common lymphoid progenitors but
not myeloid–erythryoid precursors can give rise to ILC2s [38].
Like other ILC subtypes that have recently been described (re-
viewed in [6]) and NK cells, ILC2s depend on the transcription
factor Id2 [7,39,40]. The absence of ILC2s in Rag2/Il2rg double-
deficient mice demonstrates dependency on a γc-chain cytokine.
More specifically, ILC2s found in FALCs were found to be depen-
dent on IL-7 for their development [7]. We observed pulmonary
ILC2s in mice lacking Il2rb (the β-chain of the IL-2R/IL-15R),
showing that IL-2 and IL-15 are not crucial for their development
andmaintenance, or that their function can be compensated for by
other cytokines (R.K.W., Vosshenrich et al., unpublished findings).
It is possible that the ILC2 populations that have been recently de-
scribed share a common precursor and that the local environment
plays a decisive role in their terminal differentiation.
In summary, we have shown that the novel population of ILC2
surprisingly constitutes an important fraction of IL-5 and IL-13
cytokine producing cells, next to the classical Th2 cells, in HDM
or OVA allergen-induced allergic asthma in mice. It is conceivable
that ILC2s also play a crucial role in “classical” allergic asthma
in human, because recent genome-wide association studies have
demonstrated associations with variations in genes coding for
IL-33 and its receptor ST2 [41]. ILC2s could therefore be
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an important novel target for development of future asthma
therapies.
Materials and methods
Mice and asthma induction
C57BL/6 and BALB/c mice were purchased from Harlan. All other
mice were bred and kept at the Erasmus MC Laboratory Animal
Center. Mice were kept under specific pathogen-free conditions
and provided with food and water ad libitum. Mice were 6–15
weeks at time of analysis.
In the cytokine-induced asthma models, 6-week-old anes-
thetized BALB/c mice were intranasally treated three (IL-25) or
five (IL-33 and PBS) times, with 1 μg recombinant mouse IL-25 or
IL-33 (both R&D Systems) in 50 μL PBS or PBS alone. Mice were
sacrificed and analyzed 24 h later.
For the HDM asthma protocol, 6-week-old BALB/c mice were
anesthetized using isoflurane and sensitized intratracheally using
100 μg HDM (Greer, Lenoir, NC, USA) or PBS (GIBCO, Invit-
rogen). Ten days later, mice were challenged once, three, or ten
times (three times per week) with 10 μg HDM or PBS intranasally.
Five days after the last challenge, mice were sacrificed for analysis.
OVA asthma was induced by transfer of polarized Th2 cells bear-
ing an OVA-specific TCR as described previously [42]. In brief,
DO11.10 cells obtained from lymph nodes of naive mice were
stimulated in vitro for 6 days in the presence of IL-4 (10 ng/mL,
PeproTech), anti-IFN-γ (10 μg/mL, Bioceros B.V., The Nether-
lands), anti-IL-12 (1 μg/mL), and OVA peptide (5 μg/mL, Wor-
thington Biochemical Corp). Th2 differentiation was confirmed by
flow cytometric analysis of intracellular contents for IFN-γ, IL-4,
IL-5, IL-13, and IL-17 production. After washing, 3 × 106 cells
were injected into naive BALB/c mice. Mice were challenged with
daily OVA aerosols (Sigma-Aldrich) for the subsequent 5 days and
sacrificed 48 h after the last challenge.
BAL fluid was obtained by flushing the lungs three times with
1 mL PBS containing 0.5 mM EDTA. All experiments were
approved by the Erasmus MC Animal Ethics Committee (DEC).
Preparation of single-cell suspensions
Single-cell suspensions were prepared from the spleen, lungs,
MedLNs, and BAL fluid. Spleen and lymph nodes were mechani-
cally disrupted using a 100 μm cell strainer (BD Falcon). Lungs
were mechanically disrupted using a cell strainer or digested using
collagenase type I or collagenase IV, according to the manufac-
turer’s protocol. Mesenteric and thoracic fat was digested using
2 mg/mL collagenase I in DMEM supplemented with 4% FCS
(Lonza) rocking at 37◦C for 1 h. Red blood cells from lung and
spleen were lysed using osmotic lysis buffer (NH4Cl + KHCO3 +
Na2EDTA in H2O).
Th cell cultures
For in vitro T-cell stimulations and Th1/Th2 polarization cultures,
naive CD62L+CD4+ T cells were purified by cell sorting using a
FACSAria equipped with BD FACSDiva software (BD Biosciences)
and polarized in vitro as described previously [43]. The purity of
obtained fractions was >98%.
Cell sorting, RNA extraction, and PCR
FALC cells, BAL, and lung ILC2 were purified by cell sorting
using a FACSAria. Fifty cells per well were dispensed directly
into 96-well plates and were stimulated for 4 h using IL-2,
IL-25, and IL-33 in the presence of GolgiStop. Polarized Th sub-
sets were also dispensed in 96-wells plates using a FACSAria.
After stimulation, cells were directly lysed, resuspended, and
frozen until analysis in SuperScript III One-Step RT-PCR reac-
tion buffer containing Igepal CA-630 (Sigma) and RNase Out.
Multiplex PCR was performed to directly amplify mRNA using
primers for Il4, Il5, Il6, Il13, and Actb. mRNA levels were quantified
in a nested RT-PCR reaction using MaximaTM SYBR Green/ROX
qPCR Master Mix (Fermentas) and gene-specific primers. Quan-
titative real-time PCR was performed using an Applied Biosys-
tems Prism 7700 sequence detection system. The expression of
Il5 was calculated by substraction of Actb levels from the test
mRNA, followed by calculation of the inverse log2 of the dif-
ference. Primers were ordered from Invitrogen and sequences
were as follows for external primers: Il5-extF GTGGGGGTACT-
GTGGAAATG, Il5-extR ACCAAGGAACTCTTGCAGGT, Il4-extF
ACGGATGCGACAAAAATCAC, Il4-extR TTGGAAGCCCTACAGAC-
GAG, Il6-extF GATGGATGCTACCAAACTGGA, Il6-extR TGAAG-
GACTCTGGCTTTGTCT, Il13-extF CCATCTACAGGACCCAGAGG,
Il13-extR GCGAAACAGTTGCTTTGTGT, Actb-extF CCAACCGT-
GAAAAGATGACC, Actb-extR TCTCCGGAGTCCATCACAAT. Inter-
nal primers were as follows: ActbF TCAACACCCCAGCCATGTA,
ActbR GTGGTACGACCAGAGGCATAC, Il5-forward ACATTGAC-
CGCCAAAAAGAG, Il5-reverse ATCCAGGAACTGCCTCGTC.
Flow cytometric analysis
Cells were stained with a mix of fluorescently tagged antibod-
ies in FACS buffer containing BSA. For measurements of cyto-
kine production by flow cytometry, cells were restimulated for
4 h at 37◦C using PMA and ionomycin supplemented with Gol-
giStop. After extracellular staining, cells were fixed using 4% PFA
and permeabilized using 0.5% saponin in FACS buffer. Lineage-
negative cells were gated as cells not expressing CD3, CD4, CD8α,
CD11b, CD11c, CD19, B220, NK1.1, FcεRIα, Ter-119, and Gr-1.
Purchased antibodies are described in Supporting Information Ta-
ble 1. Biotin-conjugated antibodies were detected using Pacific
Blue or allophycocyanin-Cy7-conjugated (BD) streptavidin. Data
acquisition was done using a LSR II flow cytometer equipped with
three lasers and FACSDivaTM software. Data analysis was done
using FlowJo 8.8.7 (Tree Star Inc., Ashland, OR, USA).
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Statistical analysis
For comparisons between two groups either unpaired t-tests
(normal distribution) or Mann–Whitney U tests (if no normal
distribution was expected) were used. Statistical significance of
differences between more than two groups was calculated using
one-way ANOVA analysis followed by Turkey post-tests. All anal-
yses were performed using Prism (GraphPad software, La Jolla,
CA, USA).
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